Partnering Opportunities

Velabs intends to be the preferred and prime partner of Pharma companies and Life Science oriented institutions and centers looking for a faster and more efficient development of functional therapeutic human antibodies.

Velabs either aims at partnering antibodies from its own proprietary pipeline or support antibody discovery efforts against targets of choice.
Any partnering process with Velabs will help to shorten preclinical development time and will significantly prolong partner‘s Sales & Marketing period.

Pharma Cooperations

Velabs offers its micro droplet based high speed screening services to interested life science companies. Due to its strong competitive advantage in the shortening of preclinical antibody development time, Velabs primarily offers to the Pharma industry a much faster market entry by a joint development of functional therapeutic antibodies.

BD&L Opportunities

Moreover, Velabs seeks for service cooperations with CROs, clinical centers, academic and research institutions. Velabs will support the service partner in the fast generation of novel and functional active antibodies for future pharmaceutical development or within its own service flow.


Velabs offers a set of complementary and unique microdroplet-based high speed screening services to third parties.

These services include ultra-fast screening for functional human antibodies, including the fast generation of:

Patient-derived antibodies for tumor suppression
Selective and funtional antibodies against GPCRs and ion channels
Human antibodies against pathogenic bacterial or viral strains

Tumor-specific Antibodies

  • Sampling of patient-derived human B-cells and cancer cells 
  • Droplet loading with B-cells, dye-labelled cancer cells and fluorescent secondary AB
  • Binding of primary AB from B-cells to cancer cells
  • Quantitative measurement of primary AB binding via analysis of fluorescence of secondary AB and normalization to dye signal
  • Specific sorting of droplets with positive fluorescence signal
  • Recovery of B-cells from positive droplets and sequencing of the AB-encoding genes
Quantitative analysis
of tumor-specific*
binding inside droplets
*based on the negative selection of self-recognizing ABs in the human body, hits exclusively bind tumor antigens

Functional Screening (e.g. GPCRs and Ion Channels)

  • Immunization of mice
  • Sampling of murine B-cells
  • Preparation of GPCR reporter cells
  • Droplet loading with B-cells and reporter cells
  • AB induced GPCR/Ion Channel modulation induces fluorescent signal
  • Sorting of positive droplets, B-cell recovery and sequencing of AB-encoding genes
Quantitative analysis
of target modulation inside droplets

Antibacterial Antibodies

  • Sampling of murine B-cells from immunized animals
  • Production of fluorescent bacterial strains (e.g. MRSA)
  • Droplet loading with B-cells and bacterial cells
  • Desired ABs inhibit bacterial growth upon binding to the bacterial envelope
  • Detection of decreased bacterial fluorescence
  • Sorting of positive droplets, B-cell recovery and sequencing of AB-encoding genes
Quantitative analysis
of bacterial growth
inside droplets